Top Pharma - Animal Stocks India (Week of Jun 27, 2026)

Sector Pulse

The Animal Pharma sector is demonstrating exceptional momentum, with both constituents reporting excellent financial performance and an IMPROVING demand environment. NGLFINE posted a staggering 1129.12% YoY increase in PAT to ₹15.69 Cr, while VIYASH delivered an 11% YoY revenue growth to ₹858 Cr in its first reported quarter as a merged entity. Both companies beat their margin guidance, reflecting excellent operational execution and easing input costs.

Catalysts Playing Out Across the Pack

Operating Leverage Inflection and Geographical Expansion are the dominant themes driving the sector. VIYASH is actively realizing network synergies of ₹50-60 crores post-merger and expanding into Benelux, Sweden, and Mexico. NGLFINE is driving Regulatory Approval Or License Win with 3 CEPs, 5 European ASMF approvals, and 3 US VMF filings, setting the stage for future growth in controlled markets. Additionally, VIYASH's Industry Consolidation Virtual Monopoly catalyst is fully active following the SeQuent and Viyash merger, which has already led to Interest Cost Reduction Deleveraging with net debt-to-EBITDA falling below 4x.

What Managements Are Guiding

Management tone is universally CONFIDENT. VIYASH raised its timeline to hit the ₹4,000 crore revenue target, pulling it forward from FY28 to FY27, while maintaining a 20% EBITDA margin guidance. NGLFINE raised its project capex guidance from ₹160 Cr to approximately ₹210 Cr, reaffirming its Q1FY27 commissioning timeline and projecting an asset turnover of over two times. Both companies are signaling that their current margin profiles are sustainable over the long term.

Shared Risks (9-type taxonomy)

regulatory risks are the most prominent across the sector. VIYASH faced a high-severity hit from ₹41.3 Cr in one-time merger execution expenses and a ₹7.7 Cr MAT credit reversal due to a tax regime change, though management insists these are non-recurring. VIYASH also noted minor government restrictions on specific antibiotics. Meanwhile, NGLFINE faces low-severity commodity risks, remaining exposed to raw material volatility despite recent easing. logistics risks are emerging for VIYASH as it studies the complex supply chain requirements for entering the US market.

Bottom Line

The sector is firing on all cylinders. With accelerated revenue targets, expanding margins, notable deleveraging, and aggressive geographical expansion, the fundamental setup for Animal Pharma is highly positive. While one-off regulatory and tax costs impacted statutory profits for VIYASH, the underlying operational momentum remains intact.